Breast Biopsy Market

Breast Biopsy Market Overview (2022 to 2032)

The current estimated value of the breast biopsy market is US$ 2146.54 million in 2022. By 2032, the breast biopsy market is anticipated to grow at a 5.3% CAGR and reach a value of US$ 3,596.7 million.

Increasing sensitivity of women to mammary cancer, awareness initiatives and screenings of breast biopsy, and favorable reimbursements will help the global breast biopsy market to generate great revenue in the forecasted period.

A breast biopsy is done on a small piece of tissue removed from the breast to determine the absence or presence of cancer. Fine needle aspiration biopsy is one of the least invasive procedures available and is frequently used for breast biopsies as well as leaves no scars on the breast part. In this procedure, the ultrasound monitor directs the needle to the breast's target area.

A breast biopsy is suggested when a person has symptoms including a breast lump, breast dimpling, sore breast, nipple discharge, and peeling of the breast.

Attributes	Details
Breast Biopsy Market CAGR	32.5%
Breast Biopsy Market (2022)	US$ 5.93 Billion
Breast Biopsy Market (2032)	US$ 98.93 Billion

The massive increase in women's risk of developing mammary cancer, along with screening programs and campaigns to raise awareness of the disease, is what is fueling the breast biopsy market's expansion.

Additionally, a broad and active research environment for breast biopsy has benefited from minimally invasive and the development of more accurate treatments for the early detection of breast cancer. The breast biopsy market is anticipated to grow due to the rising prevalence of breast cancer worldwide and the fact that these procedures are the least invasive.

The adoption of breast biopsy is also rising due to favorable reimbursement policies and various government initiatives, which are expected to drive the market.

Numerous negative outcomes, including significant blood loss, surgical infection, and extended recovery times, have been brought on by invasive procedures. However, the introduction of minimally invasive options like image-guided biopsy has produced reliable results. Breast biopsy market growth is anticipated to be driven by the rising acceptance of image-guided needle biopsy during the forecast period.

The surgical procedure used to conduct the biopsy tests carries risks, including the possibility of breast bruising, swelling, soreness, and infection at the site of the operation. The patient may choose to ignore some infection symptoms, such as warmth in the breasts, discharge from the site, redness in the site, or fever of more than 100°F, which could worsen the situation. These elements are impeding the market for breast biopsy expansion.

North America’s Non-invasive Approach creates a Strong Market

The North American region commands the largest market share for breast biopsy, followed by Europe. The breast biopsy market growth in the North American region is aided by the rising incidences of breast cancer and the rising demand for non-invasive treatments.

The European market for breast biopsy is anticipated to grow profitably during the anticipated period. The market for breast biopsy is expected to grow as a result of rising government spending on research studies into breast cancer and the adoption of technologically advanced treatments.

Due to their developing healthcare infrastructure, the regions of Latin America, the Middle East, and Africa are currently experiencing a period of rapid growth.

• Thermo Fisher Scientific Corp., Becton, Dickinson & Company, Hologic, Inc., Cell-Signalling Technology, Danaher, QIAGEN, Illumina, Fujifilm, Medtronic, Bio-rad, and others are on the list of important players in the market for breast biopsy. A co-exclusive commercial agreement between Becton, a preeminent global medical technology company, and Magnolia Medical Technologies, Inc., was announced today. It aims to assist American hospitals in lowering blood culture contamination in order to increase testing precision and ultimately enhance clinical outcomes.
• Launch of the Good Morning Gorgeous Sweepstakes by Hologic and Mary J. Blige serves as a wake-up call to raise awareness of the value of preventive care. The sponsorship is Hologic's most recent attempt to emphasize the value of preventive care and well-woman exams.

What are the Factors Responsible for the Growth of the Breast Biopsy Market?

The huge rise in women's susceptibility to mammary cancer, along with screenings and awareness campaigns launched in their favor, are driving the growth of the breast biopsy market. Furthermore, minimally invasive and the development of more accurate treatments for the early detection of breast cancer have benefited to broad and active research environment for breast biopsy. The increasing incidence of breast cancer worldwide and the fact that they are the least invasive procedure will expand market expansion.

Additionally, favorable reimbursements policy and various initiatives taken by the government are increasing the adoption of breast biopsy, which is expected to propel the market in the upcoming year.

Which Region Shows Strong Growth Potential in Breast Biopsy Market?

In the breast biopsy market, the North American region holds the highest market share followed by Europe. The increasing demand for non-invasive treatment and rising incidences of breast cancer will boost the market growth in the North American region.

The European market is expected to show lucrative growth in the forecasted period.

Government investment in breast cancer research studies is increasing as well as the adoption of technologically advanced treatment is anticipated to propel the breast biopsy market. Latin America, the Middle East, and Africa regions are at a blossoming stage and are expected to show sustainable growth in the near future, owing to the developing healthcare infrastructure.

Who are the Key Manufacturers of the Breast Biopsy Market?

Hologic, Inc., Becton, Dickinson, and Company, Danaher Corporation, Merit Medical Systems, Medtronic, IZI Medical Products, Argon Medical, STERYLAB S.r.l., Scion Medical Technologies LLC, QIAGEN, Biocept Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 5.3% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Million, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segment Covered	Product Indication End User Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany United Kingdom France Spain Italy China Japan South Korea Malaysia Singapore Australia New Zealand GCC Countries South Africa Israel
Key Players	Hologic, Inc. Becton Dickinson and Company Danaher Corporation Merit Medical Systems Medtronic IZI Medical Products Argon Medical STERYLAB S.r.l. Scion Medical Technologies LLC QIAGEN Biocept Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd.
Customization	Available Upon Request

Key Segments Covered in the Breast Biopsy Industry Survey

By Product:

• Biopsy Needle
  • Core Needles
  • Fine Aspiration Needles
• MRI-Guide Biopsy Systems
• Ultrasound Guided Breast Biopsy Systems
  • Two-Dimensional (2-D) Mammographic Ultrasonic Scanning Systems
  • Three-Dimensional (3-D) B-Mode Mammographic Ultrasonic Scanning Systems
• Vacuum-Assisted Device (VAD)
• Guide Wire (Localization Wire)
• Breast Biopsy Marker

By Indication:

• Complex cyst
• Solid mass
• Suspicious solid mass( fibroadenoma )
• Suspicious micro-calcifications

End User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Cancer Research Institutes

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the Growth Outlook for the Global Breast Biopsy Market?

The global breast biopsy market is anticipated to register a CAGR of 3.3% during the forecast period.

What is the Projected Value of the Global Breast Biopsy Market in 2032?

The global breast biopsy market is projected to be about US$ 1046.3 Million by the end of the year 2032.